Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Records Severance Charges of $12.8M in Q3

NEW YORK (GenomeWeb) – During its fiscal third quarter, Thermo Fisher Scientific took $12.8 million in charges related to severance, the company disclosed in its Form 10-Q filed recently with the US Securities and Exchange Commission.

Most of the charges, $8.9 million, occurred in the firm's Life Sciences Solutions segment, formed after the $13.6 billion acquisition of Life Technologies in February.

The charges follow about $40.4 million in costs that the firm recorded in the second quarter related to a headcount reduction and severance obligations to former Life Tech executives and employees and $82.7 million for such costs in the first quarter.

Additionally, the firm took $1.4 million in severance charges in its Analytical Instruments segment, which houses Thermo Fisher's mass spectrometry business among other products used in a variety of end markets, and charges of $2.5 million for severance in Specialty Diagnostics.

Across the three segments, Thermo Fisher recorded $37.6 million in net restructuring and other charges associated with headcount reductions and facility consolidations. The firm also recorded $6 million in restructuring and other charges in its corporate operations, including $800,000 for severance.

In October, Thermo Fisher reported that its Q3 2014 revenues increased 31 percent year over year to $4.17 billion, largely due to the Life Tech acquisition.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.